March 20th 2023
Combination treatment with nivolumab and relatlimab appears to be a safe treatment option for patients with advanced melanoma who have progressed on prior anti–PD-L1 therapy.
February 28th 2023
February 28th 2023
February 23rd 2023
Adjuvant Pembrolizumab Improves Quality-of-Life Vs Interferon α or Ipilimumab in Resected MelanomaDecember 5th 2022
A secondary analysis from the phase 3 SWOG S1404 trial indicated that adjuvant pembrolizumab yielded improved patient-reported outcomes compared with high-dose interferon α or ipilimumab in the treatment of patients with high-risk resected melanoma.
Adjuvant Nivolumab Demonstrates Reduced Risk of Death or Recurrence Vs Placebo in Stage IIB/C MelanomaOctober 21st 2022
Patients with completely resected stage IIB/C melanoma experienced significant and clinically meaningful improvements in recurrence-free survival following treatment with adjuvant nivolumab compared with placebo.
Optimal Sequencing of Immunotherapy Followed by BRAK/MEK Inhibitor Identified in BRAF+ Advanced MelanomaOctober 12th 2022
Findings from the phase 3 DREAMseq trial indicated that the best course of treatment for individuals diagnosed with advanced BRAF-mutated melanoma is first-line nivolumab/ipilimumab, with BRAF/MEK inhibitors used in later-line settings.
Pembrolizumab Granted 4 Approvals in Japan for High-Risk TNBC, RCC, and MoreOctober 2nd 2022
Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.
European Commission Approves Nivolumab/Relatlimab Combo for Treatment of Unresectable or Metastatic MelanomaSeptember 25th 2022
The European Commission based its approval of nivolumab/relatlimab for patients with a PD-L1 expression of less than 1% on the results of the phase 2/3 RELATIVITY-047 trial.
Adjuvant Nivolumab Yields Meaningful Improvement in RFS Vs Placebo in Stage IIB/C MelanomaSeptember 19th 2022
The positive results from the phase 3 CheckMate76K trial suggest that recurrence-free survival may be improved following treatment with adjuvant nivolumab vs placebo in fully resected stage IIB/C melanoma.
Neoadjuvant Vs Adjuvant Pembrolizumab Yields Promising EFS Benefit in High-Risk Resectable MelanomaSeptember 12th 2022
Patients with high-risk resectable melanoma experienced the highest event-free survival benefit when pembrolizumab was administered in the neoadjuvant settings vs the adjuvant setting
Efficacy of Naporafenib in NRAS-Mutant Unresectable/Metastatic Melanoma Presented at 2022 ESMOSeptember 10th 2022
Results of a phase 2 trial show favorable efficacy and tolerable safety of naporafenib in combination with rineterkib, trametinib, or ribociclib in previously treated, unresectable or metastatic melanoma.
TILs Show Better PFS vs Ipilimumab in Unresectable MelanomaSeptember 10th 2022
A randomized phase 3 trial presented at 2022 ESMO revealed better progression-free survival outcomes with tumor-infiltrating lymphocytes vs ipilimumab in stage IIIC/IV unresectable, treatment-refractory melanoma.
Jonathan S. Zager, MD, Reviews Percutaneous Hepatic Perfusion With Melphalan in Ocular Melanoma With Hepatic MetastasesSeptember 8th 2022
At ASCO 2022, Jonathan S. Zager, MD, spoke about the phase 3 FOCUS trial which analyzed patients with hepatic-dominant ocular melanoma receiving percutaneous hepatic perfusion with melphalan or best alternative care.
Atezolizumab Combination Improved Intracranial Activity in BRAF V600–Mutated Melanoma with CNS MetastasesAugust 25th 2022
Patients with BRAF V600–mutated melanoma with central nervous system metastases had positive intracranial activity following treatment with atezolizumab, vemurafenib, and cobimetinib.
Nicholas Coupe, MBBS, PhD, Provides Update on Phase 2 Study of IMM60 in Advanced Melanoma/NSCLCAugust 4th 2022
Nicholas Coupe, MBBS, PhD, discusses promising preliminary findings from a phase 1/2 study assessing the use of IMM60 in patients with advanced melanoma and non–small cell lung cancer.
Fixed-Dose Nivolumab Plus Relatlimab Showed Consistent PFS Benefit in Metastatic MelanomaJune 6th 2022
A sustained progression-free survival benefit was observed with nivolumab plus relatlimab-rmbw vs nivolumab alone in the phase 2/3 RELATIVITY-047 trial in treatment-naïve, unresectable or metastatic melanoma.
Early Data for PD-L1/IDO Peptide Vaccine Plus Standard PD-1 Inhibition Shows Promise in Metastatic MelanomaApril 8th 2022
Data from a phase 1/2 trial examining nivolumab plus a PD-L1/IDO peptide vaccine indicates early activity in patients with metastatic melanoma, according to results from the 2022 AACR Annual Meeting.
Updated Analysis of Nivolumab Plus Ipilimumab Combos Highlights Long OS for Advanced MelanomaMarch 23rd 2022
The 6.5-year updated analysis of the phase 3 CheckMate 067 trial highlighted notable overall survival benefit with nivolumab alone or in combination with ipilimumab for patients with advanced melanoma.
Fast Track Designation Granted to Novel Immunostimulant 7HP349 in Anti–PD-1 Resistant MelanomaMarch 21st 2022
7HP340 was granted fast track designation in combination with an anti–CTLA-4 treatment by the FDA for patients with unresectable or malignant melanoma for whom PD-1 inhibition therapy has failed.
Nivolumab Plus Relatlimab Demonstrates Improved OS, ORR in Untreated Metastatic or Unresectable MelanomaMarch 16th 2022
Patients with untreated metastatic or unresectable melanoma experienced numerically improved overall survival and response rates as well as long-lasting progression-free survival benefit following treatment with nivolumab and relatlimab.
Adjuvant Pembrolizumab Significantly Improved DMFS Vs Placebo in Resected Stage IIB/C MelanomaMarch 8th 2022
The phase KEYNOTE-716 trial, which assessed the use of adjuvant pembrolizumab in patients with resected stage IIB and IIC melanoma, met its secondary end point of distant metastasis-free survival.